Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.27), $0.01 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.57 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.